The ulcerative colitis pipeline
analysis report covers approximately 89 drug candidates in different stages of
development.
Ulcerative colitis is a
chronic inflammatory disease, which basically affect colonic mucosa. The main
identified symptoms of the disease are bloody diarrhea, abdominal cramps and
fatigue. Some of the other symptoms include, fever, vomiting, anorexia, abdominal
distension and bloating. The treatment approaches to this disease mostly
include the use of small molecules and monoclonal antibodies, which are being
developed to target and reduce the inflammatory mediators.Browse Detailed Report Description at: https://www.psmarketresearch.com/market-analysis/ulcerative-colitis-pipeline-analysis
The research found that different companies are engaged in the collaboration for ulcerative colitis. In June, 2015 Lycera Corp. and Celgene Corporation collaborated for the development of Lycera Corp. drug candidate for the treatment of ulcerative colitis. Celgene obtained the exclusive right to acquire Lycera upon conclusion of the option period or achievement by Lycera of pre-specified clinical milestones. During the option period, Lycera retained full control of its research and development programs.
The novel technologies are being used for ulcerative colitis drug
candidates. Protalix Ltd. is using ProCellEx technology platform for their drug
candidates. ProCellEx technology platform overcomes the weaknesses by offering
significant production, regulatory and cost benefits.
Explore Report Sample
at: https://www.psmarketresearch.com/market-analysis/ulcerative-colitis-pipeline-analysis/report-sample
Some of the key players
developing ulcerative colitis therapeutics include EA Pharma Co., Ltd., Celgene
Corporation, InDex Pharmaceuticals AB and others.
